Category Archives: Uncategorized

  • -

TENS PEMF therapy in the management of Cancer

The following studies represent some of the clinical evidence for the use of TENS PEMF therapy in the management of Cancer.

PEMF therapy for drug resistant cancer

Please note that these studies were not done on the Rife PEMF device, but rather represent studies including outputs which can be found on the various Rife Model MA devices.

ELF Magnetic field induce tumor growth inhibition and apoptosis Significant tumor growth inhibition – up to 50%. No effect on normal healthy cells. ELF at 50Hz for four weeks.
Growth of injected melanoma cells is suppressed by whole body exposure to specific spatial-temporal configurations of weak intensity magnetic fields Mice exposed to the field that was rotated through the three spatial dimensions and through all three planes every 2 sec did not grow tumors after 38 days. However, the mice in the sham-field and reference controls showed massive tumors after 38 days. Tumor growth was also affected by the intensity of the field, with mice exposed to a weak intensity field (1-5 nT) forming smaller tumors than mice exposed to sham or stronger, high intensity (2-5 microT) fields.
Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields Treatment with intrabuccally administered amplitude-modulated electromagnetic fields is safe, well tolerated, and shows

evidence of antitumor effects in patients with advanced HCC.

410 – 642Hz very low AM ELF
Low Intensity and Frequency Pulsed Electromagnetic

Fields Selectively Impair Breast Cancer Cell Viability

We observed a discrete window of vulnerability of MCF7 cells to PEMFs of 20 Hz frequency, 3 mT magnitude and

exposure duration of 60 minutes per day. The cell damage accrued in response to PEMFs increased with time and gained

significance after three days of consecutive daily exposure. By contrast, the PEMFs parameters determined to be most

cytotoxic to breast cancer MCF-7 cells were not damaging to normal MCF-10 cells.

20Hz 3mT daily for 60 minutes a day
Mechanisms and therapeutic effectiveness of pulsed

electromagnetic field therapy in oncology

 In vitro studies support antineoplastic and antiangiogenic

effects of PEMF therapy. Several mechanisms of PEMF

therapy have been elucidated. For example, PEMFs inhibit

cancer growth by disrupting the mitotic spindle in a process

mediated by interference of spindle tubulin orientation

and induction of dielectrophoresis. Furthermore, PEMF

therapy modulates gene expression and protein synthesis interacting with specific DNA sequences within gene promoter

regions [18, 38, 40, 41, 58, 103]. In addition, PEMFs

inhibit angiogenesis in tumor tissues, suppressing tumor

vascularization and reducing tumor growth, as shown by

in vivo studies [95-99, 104].

The specific claim, supported by the described in vivo

studies, is that all treated groups showed slower tumor

growth rate if compared with untreated control group,

confirming that PEMF therapy can modulate the physiology

and electrochemistry of cancer cells and influence

cell membrane systems and mitosis. In addition, PEMFs

induce some changes in membrane transport capacity

through impacting the osmotic potential, ionic valves and

leading to reduction in cellular stress factors, increase in

the rate of DNA transcription, and modulation of immune

response [105].

PEMFs have also an immunomodulatory effect, as supported

by in vivo evidence showing an increase in tumor

necrosis factor alpha levels that induce an anti-tumoral

response, leading to the activation of a proapoptotic pathway

induced by caspase-8 interaction with Fas-associated

death domain, in the spleen of the murine melanoma

mouse model after a 16-day therapy [78]. Changes in

blood pressure, skin electrical resistance, and pulse amplitude

in 163 oncology patients exposed to tumor-specific

PEMF frequencies have also been reported suggesting that

PEMF therapy does not only target neoplastic cells, but

may also have systemic effects [15]. However, long-term

PEMF treatment in HCC patients is not toxic, confirming

the safety of PEMF therapy that employs 100,000 times

lower frequencies if compared with radiofrequency ablation

that is also employed for treatment of HCC [55].

In conclusion, two clinical studies have used

PEMF therapy for cancer treatment. These studies show

that PEMF therapy is safe and promising compared to

other available cancer therapies. In the future, PEMFs

could be used not only as primary therapy but also in

combination with other common antineoplastic therapies.

Given that new portable and affordable PEMF devices

are increasingly available on the market, future controlled

clinical studies are expected to further determine the

potential of PEMF therapy in oncology

PMF sensitized fibrosarcoma and hepatocellular carcinoma to mitomycin C An article published in the Japanese Journal of Cancer research, investigated the effects of PMF therapy in combination with mitomycin C for the treatment of fibrosarcoma and hepatocellular carcinoma.[1]

WKA rats were exposed to a frequency of 200Hz immediately after IV injections of mitomycin C. The survival rates of the rats were recorded. Cultured cells were also used to study the efficacy of PMF and mitomycin C, and a combination of the two.

Survival rates of the untreated rats were 0% in the non-treated group, 34% in the group treated with mitomycin C only, and 47% for the PMF only group. For the group who received a combination of PMF and mitocycin C, the survival rate was 77%. The combination increased lifespan of the PMF mitomycin C group which was significantly prolonged at 17,6%. The efficiencies of the cells in the cultures of both cell lines were also significantly suppressed in the combination therapy group when compared with those in the other single therapy groups.

This study clearly indicates the possibility that PEMF therapy could improve and enhance the efficacy of drugs like mitomycin C.

200Hz
Low frequency EMF sensitizes cisplatin-resistant ovarian adenocarcinoma

 

Platinum based drugs like cisplatin often form the first line of therapy for cancers including testicular, bladder, esophageal cancer, lung cancer, mesothelioma, brain tumors, neuroblastoma ovarian and colorectal tumors but the use of cisplatin also often results in chemotherapy resistant cancers.[2]

In the search for a way to re-sensitize cancers to cisplatin, researchers investigated the use of extra-low frequency electromagnetic field therapy on cisplatin-resistant A2780 ovarian cancer cells. Cells were exposed to 200hz at 50 Gauss.

Researchers found that EL-EMF decreased proliferation of the cells independently of cisplatin. They also saw a decreased proliferation rate of 40 % in the cisplatin only group but the cells treated with a combination of cisplatin and EL-EMF showed a 71 % decrease in viability in rats.[3] They also saw a large increase in late apoptosis in the combination group as indicated in the graph below:

Histogram from percentage of live and dead cells from AO/PI staining for A2780 cells, data are presented as means (±SD)

The study concluded that EL-EMF therapy at 200Hz can help to sensitize cancer cells to cisplatin and improved the efficacy of cisplatin.

 

200Hz
Pulsed magnetic fields enhance the potency of daunorubicin in human carcinoma cell lines

 

Researchers studied the effects of PMF pulses of 250Hz on multidrug resistant human carcinoma cells. They inoculated mice with a multidrug resistant form of human carcinoma. They then treated the resultant tumors with pulsed magnetic therapy only or a combination of PMF therapy and daunorubicin.

Researchers found that amongst the various groups, significant differences in the tumor volume were found between PMF + saline and PMF + daunorubicin groups at 39 days and 42 days. No mice died in the PMF alone group, and no toxicity attributable to PMF was found during the experimental period.

The results indicated that the efficacy of daunorubicin was potentiated in vitro by PMF exposure when PMF exposure occurred in the presence of the drug.

250Hz
PEMF improves the effects of doxorubicin in Osteosarcoma

 

In another study, researchers studied the potential drug resistance modification effects of PEMF stimulation in multidrug resistant mouse osteosarcoma. PEMF stimulation reversed doxorubicin resistance. The concluded that PEMFs reversed the doxorubicin resistance of the MOS/ADR1 cells by inhibiting P-gp function. The results suggested that PEMFs may be useful as a local treatment for multidrug resistant osteosarcoma
50Hz enhances the antiproliferative effects of 5-fluorouracil in breast cancer

 

Finally, researchers explored the effects of pre-exposure to 50Hz to help to reduce resistance to 5-fluorouracil to enhance efficacy of the drug. The study explored the combined effect of 50 Hz-EMFs and 5-FU in the treatment of breast cancer.

Researchers found that pre-exposure to 50 Hz-EMFs enhanced the antiproliferative effect of 5-FU in breast cancer cell line MCF-7 in a dose-dependent manner but did not affect normal human breast epithelial cell lines.

They concluded that the enhanced cytotoxic activity of 5-FU on MCF7 cells through promoting entry into the S phase of the cell cycle via exposure to 50 Hz-EMFs, may provide a novel method of cancer treatment based on the combinatorial use of 50 Hz-EMFs and chemotherapy.

50Hz

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918102/

[2] https://www.ncbi.nlm.nih.gov/pubmed/21892204

[3] https://www.ncbi.nlm.nih.gov/pubmed/26370097

For more information on cancer and drug resistance please read

The Rife PEMF Model MA200 Cancer Protocol

PEMF therapy for drug resistant cancer

PEMF in cancer therapy – PEMF could be a promising modality

For more information, research and studies on TENS PEMF therapy in the management of Cancer, please join our newsletter or check back regularly for updates.

 


  • -

TENS PEMF therapy in the management of Drug Resistance Bacteria

The following studies represent some of the clinical evidence for the use of TENS PEMF therapy in the management of Drug Resistance Bacteria.

PEMF therapy for drug resistant cancer

Please note that these studies were not done on the Rife PEMF device, but rather represent studies including outputs which can be found on the various Rife Model MA devices.

For more information on TENS PEMF therapy in the management of Drug Resistance Bacteria please read: PEMF therapy for Drug Resistant Conditions or PEMF therapy for drug resistant cancer

Electromagnetic augmentation of antibiotic efficacy in infection of orthopaedic implants. Infection of orthopaedic implants is a significant problem, with increased antibiotic resistance of adherent 'biofilm' bacteria causing difficulties in treatment. We have investigated the in vitro effect of a pulsed electromagnetic field (PEMF) on the efficacy of antibiotics in the treatment of infection of implants. Five-day biofilms of Staphylococcus epidermidis were grown on the tips of stainless-steel pegs. They were exposed for 12 hours to varying concentrations of gentamicin or vancomycin in microtitre trays at 37 degrees C and 5% CO2. The test group were exposed to a PEMF. The control tray was not exposed to a PEMF. After exposure to antibiotic the pegs were incubated overnight, before standard plating onto blood agar for colony counting. Exposure to a PEMF increased the effectiveness of gentamicin against the five-day biofilms of Staphylococcus epidermidis. In three of five experiments there was reduction of at least 50% in the minimum biofilm inhibitory concentration. In a fourth experiment there was a two-log difference in colony count at 160 mg/l of gentamicin. Analysis of variance (ANOVA) confirmed an effect by a PEMF on the efficacy of gentamicin which was significant at p < 0.05. There was no significant effect with vancomycin.
Augmentation of antibiotic activity by low-frequency electric and electromagnetic fields examining Staphylococcus aureus in broth media. Systemic treatment of biomaterial-associated bacterial infections with high doses of antibiotics is an established therapeutic concept. The purpose of this in vitro study was to determine the influence of magnetic, electromagnetic, and electric fields on gentamicin-based, antibiotic therapy. It has been previously reported that these fields are successful in the treatment of bone healing and reducing osteitis in infected tibia-pseudarthroses. Four separate experimental setups were used to expose bacterial cultures of Staphylococcus aureus both in Mueller-Hinton broth (MHB) and on Mueller-Hinton agar (MHA), in the presence of gentamicin, to (1) a low-frequency magnetic field (MF) 20 Hz, 5 mT; (2) a low-frequency MF combined with an additional alternating electric field (MF + EF) 20 Hz, 5 mT, 470 mV/cm; (3) a sinusoidal alternating electric field (EF AC) 20 Hz, 470 mV/cm; and (4) a direct current electric field (EF DC) 588 mV/cm. No significant difference between samples and controls was detected on MHA. However, in MHB each of the four fields applied showed a significant growth reduction of planktonically grown Staphylococcus aureus in the presence of gentamicin between 32% and 91% within 24 h of the experiment. The best results were obtained by a direct current EF, decreasing colony-forming units (CFU)/ml more than 91%. The application of electromagnetic fields in the area of implant and bone infections could offer new perspectives in antibiotic treatment and antimicrobial chemotherapy.
Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line. Multidrug resistance (MDR) is one of the major problems in osteosarcoma chemotherapy. Therefore, methods of overcoming MDR are urgently needed. In this study, we investigated the effects of pulsing electromagnetic field stimulation (PEMFs) on a MDR murine osteosarcoma cell line which strongly expresses P-glycoprotein (P-gp). To assess the reversal effects of PEMFs on doxorubicin (DOX) resistance, MTT assay was applied. Viable cells were assessed by the trypan blue exclusion test. Fluorescence intensity of DOX binding to nuclear DNA of each cell was measured using a cytofluorometer. Changes in P-gp expression in each cell were detected by the indirect immunofluorescence method using an antibody to Pgp. PEMFs increased DOX binding ability to nuclear DNA and inhibited cell growth, although it had no significant effect on P-gp expression. These findings indicated that PEMFs reversed the DOX resistance of the MOS/ADR1 cells by inhibiting P-gp function. The results suggested that PEMFs may be useful as a local treatment for MDR osteosarcoma.

For more information, research and studies on TENS PEMF therapy in the management of Drug Resistance Bacteria, please join our newsletter or check back regularly for updates.


  • -

TENS PEMF therapy in the management of Back Pain

The following studies represent some of the clinical evidence for the use of TENS PEMF therapy in the management of Back Pain.

Please note that these studies were not done on the Rife PEMF device, but rather represent studies including outputs which can be found on the various Rife Model MA devices.

Decreased Opioid Utilization and Cost at One Year in Chronic Low Back Pain Patients Treated with Transcutaneous Electric Nerve Stimulation (TENS). Significantly fewer patients in the TENS group required opioids at final follow-up (57.7 vs. 60.3%). TENS patients also had significantly fewer annual per-patient opioid costs compared to non-TENS patients ($169 vs. $192). There were significantly lower event rates in TENS patients compared to non-TENS patients when measured by opioid utilization (characterized by frequency of prescription refills) (3.82 vs. 4.08, respectively) or pharmacy utilization (31.67 vs. 32.25). The TENS group also demonstrated a significantly lower cost of these utilization events ($44 vs. $49) and avoided more opioid events (20.4 events fewer per 100 patients annually). Various TENS devices used
Direct and Indirect Benefits Reported by Users of Transcutaneous Electrical Nerve Stimulation for Chronic Musculoskeletal Pain: Qualitative Exploration Using Patient Interviews. Data analysis indicated that distraction from pain and a reduction in the sensations associated with muscle tension or spasm should be considered as separate outcomes from pain relief. These direct benefits led to a wide range of indirect benefits dependent on patient decision making, including medication reduction, enhanced function, psychological benefits, and enhanced ability to rest. Various TENS
[Comparison of the analgesic effect of interferential current (IFC) and TENS in patients with low back pain]. After 2-weeks therapy there was improvement in the VAS and Laitinen scale (all components) in both groups, except for the part of the Laitinen scale on the reduction of activity in the group II (TENS). There was no statistically significant difference between the TENS and IF groups in reducing the intensity and other aspects of pain (frequency, pain medication and activity limitation) under the influence of therapy (p > 0.05). Interferential current and TENS therapy are effective for pain relief in patients with low back pain. The study showed equal analgesic efficacy of both treatments.  
Efficacy of pulsed electromagnetic therapy for chronic lower back pain: a randomized, double-blind, placebo-controlled study. Active PEMT (n = 17) or placebo treatment (n = 19) was performed three times a week for 3 weeks. Patients were assessed using a numerical rating scale (NRS) and revised Oswestry disability scores for 4 weeks after therapy. PEMT produced significant pain reduction throughout the observation period compared with baseline values. The percentage change in the NRS score from baseline was significantly greater in the PEMT group than the placebo group at all three time-points measured. The mean revised Oswestry disability percentage after 4 weeks was significantly improved from the baseline value in the PEMT group, whereas there were no significant differences in the placebo group. In conclusion, PEMT reduced pain and disability and appears to be a potentially useful therapeutic tool for the conservative management of chronic lower back pain.  
A Meta-Analysis of Transcutaneous Electrical Nerve Stimulation for Chronic Low Back Pain. Included were nine level I and four level II studies, encompassing 267 patients (39% male) who had a mean follow-up of seven weeks (range; 2 to 24 weeks). The mean duration of treatment was six weeks (range; 2 to 24 weeks). The standardized mean difference in pain from pre- to post-treatment for TENS was 0.844, which demonstrated significant improvement of TENS on pain reduction. Treatment of chronic low back pain with TENS demonstrated significant pain reduction. The application of TENS may lead to less pain medication usage and should be incorporated into the treatment armamentarium for chronic low back pain.  
An open-label pilot study of pulsed electromagnetic field therapy in the treatment of failed back surgery syndrome pain Relative to baseline, responders reported an average 44% and 55% reduction in back PI and leg PI (respectively), and an average 13% improvement in Oswestry Disability Index scores. In the per-protocol population, 50% of responders and 12% of nonresponders reported less analgesia consumption at the end of treatment versus baseline. Sixty-seven percent of per-protocol responders and 0% of nonresponders reported clinically meaningful improvement in overall well-being on the Patient Global Impression of Change scale  

 

Download our back pain protocol here: PEMF for Lower Back Pain – Protocol

For more information, research and studies on TENS PEMF therapy in the management of Back Pain, please join our newsletter or check back regularly for updates.


  • -

TENS PEMF therapy in the management of Autism Spectrum Disorder

The following studies represent the clinical evidence for the use of TENS PEMF therapy in the management of Autism Spectrum Disorder. Please note these studies were not done on the Rife PEMF device, but do represent outputs available on our devices.

PEMF for Boosting the Immune System

rTMS neuromodulation improves electrocortical functional measures of information processing and behavioral responses in autism Post-TMS evaluations showed decreased irritability and hyperactivity on the Aberrant Behavior Checklist (ABC), and decreased stereotypic behaviors on the Repetitive

Behavior Scale (RBS-R). Results from our study indicate that rTMS improves executive functioning in ASD as evidenced by normalization of ERP responses and behavioral reactions (RT,

accuracy) during executive function test, and also by improvements in clinical evaluations.

18 sessions of 1 Hz rTMS applied over the dorso-lateral prefrontal cortex
A double-blind, randomized trial of deep repetitive transcranial magnetic stimulation (rTMS) for autism spectrum disorder. Participants in the active condition showed a near significant reduction in self-reported social relating symptoms from pre-treatment to one-month follow-up, and a significant reduction in social relating symptoms (relative to sham participants) for both post-treatment assessments. Those in the active condition also showed a reduction in self-oriented anxiety during difficult and emotional social situations from pre-treatment to one-month follow-up. There were no changes for those in the sham condition. 5 Hz, 10-s train duration, 20-s inter-train interval) for 15 min (1500 pulses per session)
Effect of Anodal Transcranial Direct Current Stimulation on

Autism: A Randomized Double-Blind Crossover Trial

The CARS revealed a statistically significant amelioration of total score (𝑃 <0.001; Table 2). After 7 days of anodal tDCS, the tDCS group shifted from 34.95 to32.2. There was statistical change in total ATEC score observed in the active compared to sham group

(𝐹(1,39) = 23.143; 𝑃 < 0.001), as well as in health and

behavioral problem (𝐹(1,39) = 4.815; 𝑃 = 0.034), sociability

(𝐹(1,39) = 6.525; 𝑃 = 0.015), and sensory/cognitive awareness

(𝐹(1,39) = 6.171; 𝑃 = 0.018). The between group

CGAS showed statistical increase in the active compared

to sham group at 7 days after treatment (𝑃 = 0.042).

Eighteen of 20 children (90%) in the active tDCS group

demonstrated an increase in the score (from mean score

54.35 ± 11.07 at baseline to 60.00 ± 10.57 at the end of

treatment), whereas 1 of 20 children (5%) in the sham group

showed an improvement. Among those who received active tDCS, only 2 children were reported to be “minimally worse,” whereas the rest were rated as “much improved” (9 of 20) and “minimally improved” (8 of 20). This gave a response rate of 85% for active tDCS. In the sham group, 3 children were rated as

“much improved” to some extent, whereas 4 children were

reported to have “minimally improved.” Interestingly, 7 children in the sham group were rated as “worsened” after

treatment. Although the mechanisms of action of tDCS and rTMS

are not fully understood, both techniques appear to produce

similar changes in the activity of neuronal cell and thus

may lead to similar clinical outcomes

5 consecutive days of 1mA anodal or sham tDCS stimulation

(depending on order assignment) for 20 min;

Transcranial direct current stimulation for hyperactivity and noncompliance in autistic disorder. Eight out of 10 study completers improved in their abnormal behaviors, reaching an average reduction of 26.7% of the total ABC score. The remaining two patients showed no changes. In the whole group of completers, among the five subscales contributing to the significant reduction of the total score, the most remarkable and statistically significant change was seen in the subscale assessing hyperactivity and non-compliance (-35.9%, P = 0.002). No adverse effects were reported. Inhibitory tDCS improved the ABC rating scores for autistic behaviors. Owing to its ease of use, cost-effectiveness and the limited availability of specific treatment strategies, tDCS might be a valid therapeutic option to be tested in autistic patients. 10 daily applications of 20 min/1.5 mA/cathodal (inhibitory) tDCS over the left dorso-lateral pre-frontal cortex
Transcranial Direct Current Stimulation for Autistic Disorder Mr P manifested an overall substantial improvement in his abnormal behaviors, as evidenced by a 40.2% reduction in the total ABC score compared with the basal score. A direct

current of 1.5 mA was applied for 20 minutes every day.

To keep up to date on the latest studies, and clinical evidence for TENS PEMF therapy in the management of Autism Spectrum Disorder, please feel free to join our newsletter, or check back periodically.


  • -

TENS PEMF therapy in the management of Asthma and COPD

The following studies represent some of the clinical evidence for the use of TENS PEMF therapy in the management of Asthma and COPD.

Please note that these studies were not done on the Rife PEMF device, but rather represent studies including outputs which can be found on the various Rife Model MA devices.

 

Asthma and COPD

Randomized controlled trial of transcutaneous electrical muscle stimulation(TEMS) in patients with chronic COPD TEMS improved quadriceps strength (20% vs 8%), hamstring strength (13% vs 4.7%), and resulted in better performance in shuttle walk test (36% vs 1.6%) 50Hz – 20mins each limb, 3 days a week for 6 six weeks
Effects of PEMF on interleukin-1 beta and postoperative pain: a double-blind, placebo-controlled, pilot study in breast reduction patients. Mean IL-1 beta concentration in the wound exudates of treated patients was 275 percent lower (p < 0.001). Pulsed electromagnetic fields produced a 57 percent decrease in mean pain scores at 1 hour (p < 0.01) and a 300 percent decrease at 5 hours (p < 0.001), persisting to 48 hours postoperatively in the active versus the control group, along with a concomitant 2.2-fold reduction in narcotic use in active patients (p = 0.002). Unknown
Effect of TENS and AcuTens on Airway Obstructive Diseases Forced expiratory volume in treatment group increased by 13.1% and decreased in the sham group. Tens Group also increased performance in 6-minute walk test versus a decrease in the sham group. Significant increase in beta-endorphin levels in TENS group versus a decrease in the sham group. TENS has an immediate and cumulative effect on CPD and asthma. http://ira.lib.polyu.edu.hk/handle/10397/2703 2Hz Pulse
Effects of acupuncture-like transcutaneous electrical nerve stimulation on children with asthma The pediatric asthma quality-of-life questionnaire activities of the experimental group improved significantly more than those of the control group. Unknown
AcuTENS on post exercise lung volume in subjects with Asthma – Randomized controlled study Expiratory lung volume increased in treatment group versus decreasing in sham groups and this increase became more marked 20, 40 and 60 minutes after treatment 2Hz

For more information, research and studies on TENS PEMF therapy in the management of Asthma and COPD, please join our newsletter or check back regularly for updates.


  • -

Rife PEMF Patch Coils

Rife PEMF Patch Coils

The PEMF Patches allow you to take advantage of using patches which provide an effective way of supplying the TENS effect of the device in conjunction with our PEMF coil technology. Patches can be used for about 20 applications before they will need to be replaced. The patches allow you to place the coils as close to the area of application as possible. The elastics supplied with the coils allow you to secure the coils if necessary.

To purchase your Patch coils, click here.

In your patch coils you will receive:

2 large orange disks. These are the coils
2 small white adhesive patches. These are the electrode patches
2 pairs of elastics. These allow you to tie the patch coils to the area you want to treat

Wipe coils areas with a damp cloth to clean if needed. Patches are designed to last for between 10 and 20 therapy sessions. New patches can be purchased from our website or you can email us at info@rifepemf.com  

 Rife PEMF Self-Adhesive Electrodes

The self-adhesive electrodes are intended for use with the Rife PEMF device. To purchase replacement electrodes, click here.


  • -

PEMF TENS Alzheimer Update: The Alzheimer HSV1 link

It was recently brought to our attention that in many cases, the Herpes Simplex Virus 1 could play a role in Alzheimer disease which is why we are writing the PEMF TENS Alzheimer Update. According to an article in Medical News Today, there are numerous studies which now site links between the Herpes Virus and previous Herpes infections and the development and progression of Alzheimer disease.

According to studies the Herpes Virus can harm brain cells and the accumulation of damage can contribute to the development and progression of the condition.

An article in ScienceDaily outlines how scientists at the University of Edinburgh and Manchester discovered through an epidemiological study that the use of antivirals can reduce the risk of developing dementia or Alzheimer’s disease.

PEMF TENS Alzheimer

The Herpes Simplex Virus is most often associated with cold sores and antiherpetic medication could therefore potentially be used to reduce the risk of both Alzheimer’s disease and dementia.

PEMF therapy helps to support Alzheimer and Dementia patients by improving various symptoms within the disease by improving circulation, reducing inflammation and address pain and discomfort. For more information on how PEMF therapy benefits Alzheimer disease, please read our article. Studies also indicate that PEMF and TENS therapy can have beneficial outcomes for the nervous system and that PEMF and TENS therapy is generally considered safe, which makes PEMF TENS therapy a good choice for adjuvant therapy for Alzheimer patients.

PEMF TENS Alzheimer Update: The rife protocol for Alzheimer Disease

As a result of the above studies and many other PEMF TENS studies on Alzheimer disease, we have amended our Alzheimer protocol to include programs to address some of the Herpes Viruses mentioned in the above studies. For the herpes therapy, please use the Patch coils to ensure an effective whole body therapy.

The current protocol includes the program for the herpes virus available on the MA700 and some available on the MA200. To reprogram or upgrade your MA200, please feel free to email us.

 


  • -

PEMF TENS for Alzheimer disease – Research Updates

The aim of this article on PEMF TENS for Alzheimer disease is provide a simple review of the studies on the effects of electrotherapy including the effects of PEMF TENS therapy for Alzheimer’s disease.

PEMF TENS for Alzheimer’s disease

PEMF TENS for Alzheimer’s disease

This review contains 10 studies related to electrotherapy and the symptoms, progression and prognosis of Alzheimer disease. The review is not intended as an exhaustive list of studies in this area.

For an article on how PEMF TENS for Alzheimer disease can benefit patients, please feel free to read our article, “How PEMF therapy benefits Alzheimer disease.” For information on how HSV1 and the herpes virus can impact Alzheimer patients, please read our article: "PEMF TENS Alzheimer Update: The Alzheimer HSV1 link".

List of studies on PEMF TENS for Alzheimer Disease:

1.         Temporal cortex direct current stimulation enhances visual recognition in Alzheimer’s Disease Link The results showed a significant effect of stimulation condition on VRM (p = 0.0085), and post hoc analysis showed an improvement after temporal (p = 0.01) and prefrontal (p = 0.01) tDCS as compared with sham stimulation. There were no significant changes in attention as indexed by Stroop task performance. As far as is known, this is the first trial showing that tDCS can enhance a component of recognition memory 2 mA
2.         Prolonged visual memory enhancement after direct current stimulation in Alzheimer's disease Link After patients received tDCS, their performance in a visual recognition memory test significantly improved. We found a main effect of tDCS on memory performance, i.e., anodal stimulation improved it by 8.99% from baseline, whereas sham stimulation decreased it by 2.62%. tDCS failed to influence differentially general cognitive performance measures or a visual attention measure 2 mA intensity delivered for 30 minutes per day for 5 consecutive days.
3.         Transcranial direct current stimulation improves recognition memory in Alzheimer disease. Link Transcranial direct current stimulation (tDCS) delivered over the temporoparietal areas can specifically affect a recognition memory performance in patients with Alzheimer disease (AD). Because tDCS is simple, safe and inexpensive, our finding prompts studies using repeated tDCS, in conjunction with other therapeutic interventions for treating patients with AD. Unkown
4.         tDCS alongside picture training improves naming scores in Anomic dementia Link Patients treated and giving training improved 10% and 7 % over patients given no training or treatment 10 sessions 2mA over 3 weeks
5.         rTMS as a treatment for Alzheimer’s Patients who received rTMS in early stages of Alzheimer’s disease showed noticeably stronger improvement during treatment sessions 20Hz 2 second intervals
6.         Transcranial Direct Current Stimulation Modulates Cortical Neuronal Activity in Alzheimer’s Disease anodal tDCS benefits in AD patients during working memory tasks are supported by the modulation of cortical activity 1.5mA intensity for 15 min over bilateral TP areas
7.         At-home tDCS of the left dorsolateral prefrontal cortex improves visual short-term memory in mild vascular dementia. Link In patients with mild vascular dementia, anodal tDCS of the left DLPFC is able to produce additional effects to cognitive training on visual short-term memory, verbal working memory, and executive control. 2mA 20 minute sessions
8.         Alzheimer's disease: improvement of visual memory and visuoconstructive performance by treatment with picotesla range magnetic fields Link The report demonstrates, for the first time, that specific cognitive symptoms of AD are improved by treatment with EMF of a specific intensity and frequency. The rapid improvement in cognitive functions in response to EMF suggests that some of the mental deficits of AD are reversible being caused by a functional (i.e., synaptic transmission) rather than a structural (i.e., neuritic plaques) disruption of neuronal communication in the central nervous system. the range of 5Hz-8Hz
9.         Value and Efficacy of Transcranial Direct Current Stimulation in the Cognitive Rehabilitation: A Critical Review Since 2000 Link … “most of the studies reviewed reported a positive

Effect of tDCS in all these neurocognitive disorders”

Various
10.     Adjunctive treatment with high frequency repetitive

transcranial magnetic stimulation for the behavioral and

psychological symptoms of patients with Alzheimer’s disease:

a randomized, double-blind, sham-controlled study
Link

Conclusion: Compared to treatment of AD with low-dose antipsychotic medications alone, the combination

of low-dose antipsychotic medication with adjunctive treatment with high frequency rTMS can significantly

improve both cognitive functioning and the behavioral and psychological symptoms that often accompany

Alzheimer’s disease.

20Hz rTMS five days a week for four weeks

Please also see our protocol for Alzheimer disease here: Protocol for PEMF TENS for Alzheimer disease

Click here to reserve your Model MA200 or MA700 today


  • -
PEMF therapy for drug resistant cancer

PEMF therapy for drug resistant cancer

PEMF therapy for drug resistant cancer may soon be a reality. Cancer therapies are often presented to the patients in a Hobson’s choice type of approach. They either follow conventional therapy or alternative therapies which often feel like an impossible choice, particularly when most people when faced with a life-threatening condition, would choose to do everything they possibly can. Now cancer patients don’t have to make a choice between chemotherapy and PEMF therapy.

PEMF therapy for drug resistant cancer

For the first time the FDA has approved the use of tumor treating fields for the treatment of some types of brain cancer in conjunction with surgery, chemotherapy and radiation.[1]

There have been major strides in studying the effects of electric and magnetic fields in the possible treatment of cancer over the last few years. Some of these studies were outlined in our article “Pemf in cancer therapy – Pemf could be a promising modality.” Most of these studies have focused on the use of low frequency therapy as a treatment modality on its own, but now there are studies that indicate that a combination of PEMF and chemotherapy could be an excellent option for cancer patients, particularly those with chemo-resistant cancers.

With the emergence of drug resistant and multidrug resistant cancers, scientists have been frantically searching for ways to re-sensitize cancers to drugs which offer some hope for cancer patients. Enhancing the effects of chemotherapy drugs like cisplatin, doxorubicin, daunorubicin, 5-fluorouracil (Adrucil) and mitomycin C and the ability re-sensitize cancer cells to these drugs, may offer a novel approach to cancer therapy and new treatment options for cancer patients who have developed drug resistance.

In summary, studies have found that:

  • PEMF sensitized fibrosarcoma and hepatocellular carcinoma to mitomycin C
  • Low frequency EMF sensitized cisplatin-resistant ovarian adenocarcinoma
  • Pulsed magnetic fields enhanced the potency of daunorubicin in human carcinoma cell lines
  • PEMF improved the effects of doxorubicin in Osteosarcoma
  • 50Hz low frequency exposure enhanced the antiproliferative effects of 5-fluorouracil in breast cancer

The great news is that not only did PEMF therapy support and promote the efficacy of chemotherapy, but PEMF has already been approved as a pain therapy and the MA200 is an approved medical device in South Africa. PEMF therapy has also been shown to have an excellent safety profile with almost no adverse events being reported in thousands of clinical trials on pain and other conditions.

Adding PEMF therapy to a cancer and chemotherapy protocol poses very few, if any risks at all, and can provide numerous benefits for a cancer patient. The frequencies used in the studies are all available on the MA200. Finally, PEMF therapy is a cost-effective therapy for the cancer patient, with options from as little as R499 per month for the rental of an MA200 device.

PEMF therapy for drug resistant cancer - Summary of Studies

The following are summaries of the studies mentioned above, with references to those studies on Pubmed.

PEMF therapy for drug resistant cancer - PMF sensitized fibrosarcoma and hepatocellular carcinoma to mitomycin C

An article published in the Japanese Journal of Cancer research, investigated the effects of PMF therapy in combination with mitomycin C for the treatment of fibrosarcoma and hepatocellular carcinoma.[2]

WKA rats were exposed to a frequency of 200Hz immediately after IV injections of mitomycin C. The survival rates of the rats were recorded. Cultured cells were also used to study the efficacy of PMF and mitomycin C, and a combination of the two.

Survival rates of the untreated rats were 0% in the non-treated group, 34% in the group treated with mitomycin C only, and 47% for the PMF only group. For the group who received a combination of PMF and mitocycin C, the survival rate was 77%. The combination increased lifespan of the PMF mitomycin C group which was significantly prolonged at 17,6%. The efficiencies of the cells in the cultures of both cell lines were also significantly suppressed in the combination therapy group when compared with those in the other single therapy groups.

This study clearly indicates the possibility that PEMF therapy could improve and enhance the efficacy of drugs like mitomycin C.

PEMF therapy for drug resistant cancer - Low frequency EMF sensitizes cisplatin-resistant ovarian adenocarcinoma

Platinum based drugs like cisplatin often form the first line of therapy for cancers including testicular, bladder, esophageal cancer, lung cancer, mesothelioma, brain tumors, neuroblastoma ovarian and colorectal tumors but the use of cisplatin also often results in chemotherapy resistant cancers.[3]

In the search for a way to re-sensitize cancers to cisplatin, researchers investigated the use of extra-low frequency electromagnetic field therapy on cisplatin-resistant A2780 ovarian cancer cells. Cells were exposed to 200hz at 50 Gauss.

Researchers found that EL-EMF decreased proliferation of the cells independently of cisplatin. They also saw a decreased proliferation rate of 40 % in the cisplatin only group but the cells treated with a combination of cisplatin and EL-EMF showed a 71 % decrease in viability in rats.[4] They also saw a large increase in late apoptosis in the combination group as indicated in the graph below:

Histogram from percentage of live and dead cells from AO/PI staining for A2780 cells, data are presented as means (±SD)

The study concluded that EL-EMF therapy at 200Hz can help to sensitize cancer cells to cisplatin and improved the efficacy of cisplatin.

PEMF therapy for drug resistant cancer - Pulsed magnetic fields enhance the potency of daunorubicin in human carcinoma cell lines

Researchers studied the effects of PMF pulses of 250Hz on multidrug resistant human carcinoma cells. They inoculated mice with a multidrug resistant form of human carcinoma. They then treated the resultant tumors with pulsed magnetic therapy only or a combination of PMF therapy and daunorubicin.

Researchers found that amongst the various groups, significant differences in the tumor volume were found between PMF + saline and PMF + daunorubicin groups at 39 days and 42 days. No mice died in the PMF alone group, and no toxicity attributable to PMF was found during the experimental period.

The results indicated that the efficacy of daunorubicin was potentiated in vitro by PMF exposure when PMF exposure occurred in the presence of the drug.[5]

PEMF therapy for drug resistant cancer - PEMF improves the effects of doxorubicin in Osteosarcoma

In another study, researchers studied the potential drug resistance modification effects of PEMF stimulation in multidrug resistant mouse osteosarcoma. PEMF stimulation reversed doxorubicin resistance. The concluded that PEMFs reversed the doxorubicin resistance of the MOS/ADR1 cells by inhibiting P-gp function. The results suggested that PEMFs may be useful as a local treatment for multidrug resistant osteosarcoma.[6]

PEMF therapy for drug resistant cancer - 50Hz enhances the antiproliferative effects of 5-fluorouracil in breast cancer

Finally, researchers explored the effects of pre-exposure to 50Hz to help to reduce resistance to 5-fluorouracil to enhance efficacy of the drug. The study explored the combined effect of 50 Hz-EMFs and 5-FU in the treatment of breast cancer.

Researchers found that pre-exposure to 50 Hz-EMFs enhanced the antiproliferative effect of 5-FU in breast cancer cell line MCF-7 in a dose-dependent manner but did not affect normal human breast epithelial cell lines.

They concluded that the enhanced cytotoxic activity of 5-FU on MCF7 cells through promoting entry into the S phase of the cell cycle via exposure to 50 Hz-EMFs, may provide a novel method of cancer treatment based on the combinatorial use of 50 Hz-EMFs and chemotherapy.[7]

[1] http://www.bendwellnessdoctor.com/index.php?p=513073

[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918102/

[3] https://www.ncbi.nlm.nih.gov/pubmed/21892204

[4] https://www.ncbi.nlm.nih.gov/pubmed/26370097

[5] https://www.ncbi.nlm.nih.gov/pubmed/9216668

[6] https://www.ncbi.nlm.nih.gov/pubmed/11299755

[7] https://www.ncbi.nlm.nih.gov/pubmed/29617363


  • -

TENS therapy for ADHD – ADHD Alternatives to medication

For most of us, sitting still and concentrating on something we want to do, or need to, is a fairly simple task but for those struggling with ADHD, simple tasks can be near impossible. Although there are several medications which can be beneficial for patients with ADHD, more and more people are searching for ADHD alternatives to medication. TENS therapy for ADHD may be the alternative they are looking for. In fact, often TENS and other electrotherapies can be used along with other therapies.

TENS therapy for ADHD

Symptoms of ADHD include an inability to pay attention, making careless mistakes, not being able to listen efficiently, inability to follow through on instructions, difficulty organizing, being easily distracted, forgetful and constant fidgeting or an inability to remain seated or calm. For parents of ADHD children, these symptoms can severely impact on home and school life and for adults, these symptoms can interfere with the ability to be efficient at work and may even prevent a person from securing a job.

Therapies that can help to reduce the symptoms by improving concentration, memory and other cognitive functions, can therefore change lives.

TENS therapy, rTMS, and TDCs all use micro-current electricity to stimulate the brain to support, improve and address various cognitive functions. There are some promising research papers dealing with rTMS, tDCS and TENS therapy for ADHD and we hope to share some of those studies with you here.

Studies on rTMS, tDCS and TENS Therapy for ADHD

In the first study, researchers studied the effects of TENS therapy on 22 children who had been diagnosed with ADHD of the combined type. The children were given treatments for 6 weeks, twice a day for 30 minutes per session. The results of the study concluded that TENS therapy for ADHD in this was encouraging and further studies were recommended. The study showed that tens seemed to have a moderate beneficial influence on the cognitive functions of the children involved in the study.

In 2012, researchers studied the effects of TMS or transcranial stimulation on the treatment of ADHD. The study consisted of 9 young adults between the ages of 15 and 20. This study used 10Hz and included a sham group as part of the study. The study concluded that rTMS was safe for use in adolescents and the researchers reports an improvement in core ADHD symptoms in the active group.

In 2010, a study was conducted to asses the positive effects of rTMS on subjects with ADHD and they found that rTMS had positive effects in 13 patients involved in the study.

1Hz stimulation has also been studied in rTMS and TENS therapy for ADHD. Researchers applied 1Hz on the motor area of the scalp in patients affected with ADHD and they found significant improvement in the patients and they also reported that the improvements lasted for 4 weeks. There was no improvement in the sham group in this trial.

TDCS therapy has also been shown to improve symptoms in young adults with ADHD. 15 children aged 12 to 16, diagnosed with ADHD, were included in a random sham-controlled study where 1mA anodal TDCS was administered for 5 days each followed by a two week pause in therapy. The therapy showed a significant reduction in the symptoms of impulsivity and inattention. The results were supported by a decrease in hyperactivity and inattention in the QbTest – the standardized working memory test. The study concluded that the results provide evidence that tDCS may help to reduce the symptoms of ADHD and they offer proof of improved neuropsychological functioning in young ADHD patients.

Finally, in a sham-controlled, randomized clinical trial, researchers evaluated the effects of 2mA tDCS therapy on 17 patients who had been diagnosed with ADHD. The patients received 5 days of therapy with the anode over the right prefrontal cortex. They measured ADHD symptoms using the ADHD Self report scale and they also measured impairment using the SDS scale. They found that therapy resulted in significantly lower ASRS and SDS scores when compared to the sham group. They also observed that the improved symptoms continued after the treatment.

Safety of tTMS, TDCS and TENS therapy for ADHD

In the review of non-invasive brain stimulation for ADHD, researchers made a number of remarks regarding the safety of TENS therapy for ADHD. According to the revierw, over 800 normal and 300 neurologically abnormal children had received therapy with good tolerability and safety.

Studies showed there had been no changes in auditory function, the therapy did not cause seizures in children including those with epilepsy. There was no increased risk in seizures in children with cerebral palsy. According to their research, one case of seizure in rTMS therapy was reported in the treatment of depression although that case had other risk factors present which increased seizure risk.

In 2009, a consensus conference issued recommendations for the safe use TMS in the pediatric population that single-pulse and paired-pulse TMS was safe for children two years and older.

Obviously, if you are investigating the benefits of TENS therapy for ADHD and you are considering investing in a model MA200 device, then we suggest you work with a medical practitioner both for diagnostic and prognosis of the condition.

Conclusions on TENS therapy for ADHD

Most of the studies on TENS therapy for ADHD have concluded that TENS and other therapies like tDCS and rTMS hold potential benefits for ADHD patients. The interesting thing to note is that most of these therapies, like TENS and tDCS are also often compatible with many of the medications used so these therapies can often be used in conjunction with other medication and therapies to address the symptoms of ADHD.

This means that, working with your practitioner, you can add TENS therapy to your choice of therapies without having to discontinue other therapies or medications. Since TENS therapies may be advantageous for other things like improving memory, and even improving sleep, TENS therapy may offer a comprehensive approach which can be included in ADHD therapy making TENS therapy of ADHD a viable addition to various treatment protocols.


Cart